ImunoTera is a spin off from University of Sao Paulo (USP), considered the best university in
Latin America 2021. The startup was founded in 2016 by three researchers who developed a
biotech platform capable of restoring and activating the immune system to fight infectious
diseases and cancer. The company has received more than R$ 2 million (BRL) in research
projects and was recently invested by Biotechtown, one of the largest accelerators of biotechnology companies in Brazil. In 2020, ImunoTera was one of the winners of the Innovative Women Award. ImunoTera’s technological platform is based on a dual-function protein designed with therapeutic precision to target various types of cancer and pathogens. The pipeline so far includes therapeutic vaccines to control HPV-related cancer, HIV, ZIKV and SARS-CoV-2. These strategies have proven to generate strong effector responses in animal models. Our first product, the TERAH-7 is currently being applied in an experimental clinical study based on cell therapy, where dendritic cells from patients diagnosed with CIN are activated in vitro with the protein and infused into patients in an autologous manner. Preliminary results are showing
complete regression of CIN, avoiding the need for surgery in some treated patients.
Latin America 2021. The startup was founded in 2016 by three researchers who developed a
biotech platform capable of restoring and activating the immune system to fight infectious
diseases and cancer. The company has received more than R$ 2 million (BRL) in research
projects and was recently invested by Biotechtown, one of the largest accelerators of biotechnology companies in Brazil. In 2020, ImunoTera was one of the winners of the Innovative Women Award. ImunoTera’s technological platform is based on a dual-function protein designed with therapeutic precision to target various types of cancer and pathogens. The pipeline so far includes therapeutic vaccines to control HPV-related cancer, HIV, ZIKV and SARS-CoV-2. These strategies have proven to generate strong effector responses in animal models. Our first product, the TERAH-7 is currently being applied in an experimental clinical study based on cell therapy, where dendritic cells from patients diagnosed with CIN are activated in vitro with the protein and infused into patients in an autologous manner. Preliminary results are showing
complete regression of CIN, avoiding the need for surgery in some treated patients.
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
